Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial-Reference-Cited by-同舟云学术

Long-term efficacy and safety of ixekizumab: A 5-year analysis of the UNCOVER-3 randomized controlled trial

Published:2021-08 Issue:2 Volume:85 Page:360-368
ISSN:0190-9622
Container-title:Journal of the American Academy of Dermatology
language:en
Short-container-title:Journal of the American Academy of Dermatology

Author:

Blauvelt Andrew,Lebwohl Mark G.,Mabuchi Tomotaka,Leung Ann,Garrelts Alyssa,Crane Heidi,ElMaraghy Hany,Patel Himanshu,Ridenour Terri,See Kyoungah,Gallo Gaia,Paul Carle

Funder

Eli Lilly and Company

Publisher

Elsevier BV

Subject

Dermatology

Reference16 articles.

1. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics;Menter;J Am Acad Dermatol,2019

2. Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3);Blauvelt;J Am Acad Dermatol,2017

3. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials;Griffiths;Lancet,2015

4. Ixekizumab sustains high level of efficacy and favourable safety profile over 4 years in patients with moderate psoriasis: results from UNCOVER-3 study;Lebwohl;J Eur Acad Dermatol Venereol,2020

5. Maintenance of skin clearance with ixekizumab treatment of psoriasis: three-year results from the UNCOVER-3 study;Leonardi;J Am Acad Dermatol,2018

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. IL-17 inhibitors in axial spondyloarthritis. An overview;Expert Opinion on Biological Therapy;2024-08-21

2. Biologics for Psoriasis;Dermatologic Clinics;2024-07

3. Long-Term Effectiveness and Safety of Ixekizumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A Five-Year Multicenter Retrospective Study—IL PSO (Italian Landscape Psoriasis);Dermatology and Therapy;2024-05-15

4. The Safety of Ixekizumab in Chinese Adults with Moderate-to-Severe Plaque Psoriasis: Analyses from a Prospective, Single-Arm, Multicenter, 12-Week Observational Study;Drug Safety;2024-04-30

5. Assessing the 5-year persistence in positive clinical response with innovative psoriasis treatments: a network meta-analysis of Psoriasis Area and Severity Index score;Clinical and Experimental Dermatology;2024-04-15